Jordan Neysmith serves as the Vice President of Engineering at Element Biosciences, a position he assumed in mid-2021 following a significant Series C funding round where the company raised $276 million to advance its DNA sequencing technology platform. Element Biosciences is a life sciences firm focused on developing disruptive DNA sequencing technologies aimed at research and diagnostic markets.
Prior to joining Element Biosciences, Neysmith held senior roles including Senior Director of Development and Engineering at Bruker Nano Surfaces and executive positions at Bausch Health and McKinsey, underscoring a strong background in technology leadership, research, development, and product management within highly innovative environments.
Educationally, Jordan Neysmith holds a Bachelor of Science in Mechanical Engineering from Yale University and a Master of Science in Mechanical Engineering from the Georgia Institute of Technology. This technical foundation complements his extensive engineering and leadership experience.
In his current role at Element Biosciences, Neysmith leads engineering efforts critical to the development and commercialization of their novel sequencing platform. The company has pioneered a proprietary sequencing chemistry known as "avidity sequencing", which distinctly optimizes stepping along DNA templates independently from nucleotide identification, resulting in high accuracy with reduced reagent consumption. This innovation positions the company as a notable competitor in next-generation sequencing technologies.
Recent publications and scientific contributions at Element Biosciences that involve Neysmith include work on:
- Avidity sequencing chemistry, validated in top-tier scientific journals in 2023 and 2024.
- Multiomics profiling platforms integrating high-throughput DNA and RNA sequencing instrumentation.
- Advancements in scalable co-sequencing of RNA and DNA at the single-cell level.
These technical achievements demonstrate that under Neysmith’s engineering leadership, Element Biosciences is advancing cutting-edge sequencing technologies that focus on performance, scalability, and cost-efficiency for both research and clinical applications.
His public LinkedIn communications highlight a leadership style that emphasizes team impact and resourcefulness within R&D divisions, aligning engineering development with the company's broader scientific innovation goals. This indicates Neysmith's integral role in driving product and technology strategy at the company.
Overall, Jordan Neysmith’s profile is characterized by a strong engineering pedigree combined with executive leadership across technology development stages. His role at Element Biosciences is pivotal in delivering the company’s innovative DNA sequencing solutions to market, supported by substantial recent capital investment and a clear focus on commercialization and technology differentiation.
